Bupivacaine implant - Innocoll

Drug Profile

Bupivacaine implant - Innocoll

Alternative Names: B-Implant; Bupivacaine-collagen bioresorbable implant - Innocoll; CollaRx® Bupivacaine implant; INL-001; INN-LD-01; XaraColl

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Innocoll
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain
  • No development reported Pain

Most Recent Events

  • 29 Dec 2016 The US FDA issues a Refusal to File letter regarding NDA for bupivacaine implant for Postoperative pain
  • 30 Oct 2016 Preregistration for Postoperative pain in USA (9209450; 9206363)
  • 25 May 2016 Pooled efficacy and adverse events data from phase III MATRIX-1 and MATRIX-2 trials in Postoperative pain released by Innocoll
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top